Abstracts tagged "Systemic sclerosis"

Abstract Number: 0407 • ACR Convergence 2021
The Clinical Role of T1 Mapping Cardiac Magnetic Resonance Imaging for Detecting Cardiac Involvement in the Early Stage of Systemic Sclerosis
Munkhtuul Purevsuren¹, Masae Uehara¹, Masato Ishizuka¹, Toru Hara¹, Nobutaka Kakuda¹, Taeko Tsuji¹, Tadashi Yamazaki¹, Miyazaki Miki², Hayakazu Sumida², Ayumi Yoshizaki², Yoshihide Asano², Shinichi Sato³, Masaru Hatano¹ and Komuro Issei¹, ¹1. Department of Cardiovascular Medicine, The University of Tokyo, Graduate School of Medicine, Tokyo, Japan., Tokyo, Japan, ²2. Department of Dermatology, The University of Tokyo, Graduate School of Medicine, Tokyo, Japan., Tokyo, Japan, ³Department of Dermatology, The University of Tokyo, Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Systemic sclerosis (SSc) is characterized by skin and internal organs tissue fibrosis including the myocardium. Cardiovascular magnetic resonance (CMR) parametric mapping is a promising…
Abstract Number: 0557 • ACR Convergence 2021
The Beta Secretase BACE1 Induces Systemic Sclerosis (SSc) Fibroblast Activation Through the Regulation of the Pro-Fibrotic Notch Signalling Pathway
Christopher Wasson¹, Eva Clavane², Rebecca Ross¹, Paul Meakin² and Francesco Del Galdo³, ¹LIRMM University of Leeds, Leeds, United Kingdom, ²LICAMM University of Leeds, Leeds, United Kingdom, ³University of Leeds, Leeds, United Kingdom
Background/Purpose: Extensive work in the Alzheimer’s field has shown BACE1 plays an important role in amyloid beta processing. Additionally, there is evidence showing BACE1 regulating…
Abstract Number: 1150 • ACR Convergence 2021
Use of Energy Conversation Strategies as a Result of the Fatigue Management Education for Individuals with Systemic Sclerosis (FAME-iSS)
Janet Poole¹, Deirdre Connolly² and Kristine Carandang³, ¹University of New Mexico, Albuquerque, NM, ²Trinity Centre for Health Sciences, Dublin, Ireland, ³Independent, San Diego, CA
Background/Purpose: Fatigue remains an understudied symptom of systemic sclerosis (SSc). For other diagnoses, increasing the use of energy conservation strategies, especially pacing. has been associated…
Abstract Number: 1387 • ACR Convergence 2021
Macrovascular Dysfunction and Its Clinical Implication in Systemic Sclerosis
Devender Bairwa¹, Chengappa Kavadichanda², sanket Shah³, Anoop Mathew¹, saikumar dunga³, Aishwarya Gopal³, Molly Mary Thabah¹ and VirSingh Negi¹, ¹Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India, ²JIPMER, Pondicherry, India, ³Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India
Background/Purpose: Microvascular dysfunction is a key and determining feature of scleroderma (SSc). But contrary to earlier belief there is emerging evidence to suggest co-occurrence of…
Abstract Number: 1844 • ACR Convergence 2021
Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated ILD (SSc-ILD) and Differing Comorbidity Burden: Subgroup Analyses of the SENSCIS Trial
Kristin B Highland¹, Teng Moua², Martin Aringer³, Takashi Ogura⁴, Corinna Miede⁵, Margarida Alves⁶ and Virginia Steen⁷, ¹Cleveland Clinic, Cleveland, OH, ²Division of Pulmonary and Critical Care Medicine, Mayo Clinic Rochester, Rochester, MN, ³Rheumatology, Medicine III, University Medical Center & Faculty of Medicine, TU Dresden, Dresden, Germany, ⁴Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Centre, Yokohama, Japan, ⁵mainanalytics GmbH, Sulzbach (Taunus), Germany, Sulzbach, Germany, ⁶Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim, Germany, ⁷Division of Rheumatology, Georgetown University, Washington, DC
Background/Purpose: In the SENSCIS trial in patients with SSc-ILD, nintedanib reduced the rate of decline in forced vital capacity (FVC) vs placebo. Patients with SSc-ILD…
Abstract Number: 0293 • ACR Convergence 2021
Increased Prevalence of Scleroderma Specific Autoantibodies in Seropositive Rheumatoid Arthritis with Lung Involvement
Vasiliki Koulouri¹, Kyriaki Tavernaraki², Mayra Giannelou³ and Clio Mavragani¹, ¹National and Kapodistrian University of Athens, Athens, Greece, ²Imaging and Interventional Radiology, Sotiria General and Chest Diseases Hospital, Athens, Greece, ³Department of Rheumatology, General Hospital of Athens "G. Gennimatas", Athens, Greece
Background/Purpose: To evaluate the prevalence of scleroderma (SSc) specific and anti-Ro52 autoantibodies in seropositive rheumatoid arthritis (RA) patients with lung involvement.Methods: Sera from 67 seropositive…
Abstract Number: 0409 • ACR Convergence 2021
Factors Predicting Mortality in an Indian Cohort of Systemic Sclerosis
T G Sundaram¹, Durga P Misra¹, Rudrarpan Chatterjee¹, Sakir Ahmed² and Vikas Agarwal³, ¹Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India, ²Kalinga Institute of Medical Sciences, Bhubaneswar, India, ³Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: Systemic sclerosis is characterised by high morbidity and mortality due to disease-related or treatment-related complications.Methods: Data of patients of systemic sclerosis between 1990 and…
Abstract Number: 0558 • ACR Convergence 2021
The Systemic Sclerosis (SSc) Risk Gene A20 (TNFAIP3) and Its Repressor DREAM Determine Susceptibility to Fibrosis
Swarna Bale¹, Wenxia Wang², Roberta G Marangoni³, Erica Herzog⁴, Bettina C Schock⁵, Swati Bhattacharyya¹ and Varga John¹, ¹University of Michigan, Ann Arbor, MI, ²Northwestern University, Chicago, IL, ³University of Rochester, Rochester, NY, ⁴Yale University School of Medicine, New Haven, CT, ⁵Wolfson Institute for Experimental Medicine, Queens University, Belfast, United Kingdom
Background/Purpose: The ubiquitin-editing enzyme A20, encoded by TNFAIP3, is genetically implicated in autoimmune and inflammatory diseases. A20 plays a pivotal role in regulating inflammatory cellular…
Abstract Number: 1364 • ACR Convergence 2021
Autologous Hematopoietic Stem Cell (HSC) Transplantation for Systemic Sclerosis, North American Registry: Updated Outcomes and the Impact of CD34+ HSC Enrichment
George Georges¹, Keith Sullivan², Dinesh Khanna³, Matthew Mei⁴, Maureen Mayes⁵, Dan Furst⁶, Mark Wener⁷, Suzanne Kafaja⁸, Gwynn Long², Vaishali Sanchorawala⁹, Kareem Jamani¹⁰, Attaphol Pawarode³, Ashish Masurekar¹¹, Brian Lam¹², Richard Nash¹³, Marcin Trojanowski⁹, Chitra Hosing¹⁴, Philip Clements¹⁵, Tanya Helms², Bernadette McLaughlin¹⁶, Linda Griffith¹⁷, Kyle Hebert¹⁸, Mary Eapen¹⁸, Jan Storek¹⁰ and Harold Atkins¹¹, ¹Fred Hutchison Cancer Research Center and University of Washington, Seattle, WA, ²Duke University School of Medicine, Durham, NC, ³University of Michigan, Ann Arbor, MI, ⁴City of Hope Comprehensive Cancer Center, Duarte, CA, ⁵Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, TX, ⁶University of California Los Angeles, Los Angeles, CA, ⁷University of Washington, Seattle, WA, ⁸University of California Los Angeles Division of Rheumatology, Los Angeles, CA, ⁹Boston University School of Medicine, Boston, MA, ¹⁰University of Calgary, Calgary, AB, Canada, ¹¹Ottawa Hospital Research Institute, Ottawa, ON, Canada, ¹²University of Texas McGovern Medical School, Houston, TX, ¹³Colorado Blood Cancer Institute, Denver, CO, ¹⁴University of Texas MD Anderson Cancer Center, Houston, TX, ¹⁵University of California Los Angeles School of Medicine, Department of Rhemumatology, Los Angeles, CA, ¹⁶Fred Hutchison Cancer Research Center, Seattle, WA, ¹⁷Division of Allergy Immunology and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, ¹⁸Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Autologous hematopoietic stem cell transplantation (AHSCT) is now established as a preferred standard of care treatment for patients with severe scleroderma with internal organ…
Abstract Number: 1390 • ACR Convergence 2021
A 5% Increase in Interstitial Lung Disease at 1-Year Follow-up Is Associated with Long-Term ILD Progression in Systemic Sclerosis
Alicia Hinze¹, Shreyasee Amin¹, Ashima Makol¹, Robert Vassallo¹, Cynthia Crowson² and Brian Bartholmai¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Eyota, MN
Background/Purpose: The clinical course of interstitial lung disease (ILD) in systemic sclerosis (SSc) is highly variable. Some patients experience a progressive decline in lung function…
Abstract Number: 1845 • ACR Convergence 2021
Six-minute Walk Test as a Prognostic Marker in Systemic Sclerosis
Vinicius Verlangieri Soubihe, Juliana Zonzini Gaino, Alisson Pugliesi, Ana Paula Toledo Del Rio, Zoraida Sachetto, Marília Paula Souza Dos Santos and Luciana Campanatti Palhares, University of Campinas, Campinas, Brazil
Background/Purpose: Pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD) are the leading causes of mortality in systemic sclerosis (SSc). Although the six-minute walk test…
Abstract Number: 0389 • ACR Convergence 2021
Use of Nintedanib for the Treatment of Systemic Sclerosis-associated Interstitial Lung Disease at Expert Scleroderma Centers in the United States
Elana Bernstein¹, John VanBuren², Shervin Assassi³, Flavia Castelino⁴, Lorinda Chung⁵, Chase Correia⁶, Luke Evnin⁷, Tracy Frech², Emily Startup², Jessica Gordon⁸, Faye Hant⁹, Laura Hummers¹⁰, Nora Sandorfi¹¹, Ami Shah¹², Victoria Shanmugam¹³, Virginia Steen¹⁴ and Dinesh Khanna¹⁵, ¹Columbia University, New York, NY, ²University of Utah, Salt Lake City, UT, ³University of Texas McGovern Medical School at Houston, Houston, TX, ⁴Massachusetts General Hospital, Boston, MA, ⁵Stanford University, Palo Alto, CA, ⁶Northwestern University, Chicago, IL, ⁷Scleroderma Research Foundation, Brisbane, CA, ⁸Hospital for Special Surgery, New York, NY, ⁹Medical University of South Carolina, Charleston, SC, ¹⁰Johns Hopkins Univerisity, Baltimore, MD, ¹¹University of Pennsylvania, Philadelphia, PA, ¹²Johns Hopkins Rheumatology, Baltimore, MD, ¹³The George Washington University, Great Falls, VA, ¹⁴Division of Rheumatology, Georgetown University, Washington, DC, ¹⁵University of Michigan, Ann Arbor, MI
Background/Purpose: Interstitial lung disease (ILD) affects 40-60% of adults with systemic sclerosis (SSc) and is the leading cause of death in this population. Nintedanib, a…
Abstract Number: 0410 • ACR Convergence 2021
Long-term Outcomes of Vascular Grafting of Medium Sized Vessels of the Wrist and Hand in Patients with Medication Refractory Systemic Sclerosis Related Raynaud’s Phenomenon at the University of Pennsylvania from 2009-2019
Nora Sandorfi¹, Chris Derk² and Nora Hajnoczky³, ¹University of Pennsylvania, Philadelphia, ²University of Pennsylvania, Philadelphia, PA, ³Albert Einstein Healthcare Network, Wallingford, PA
Background/Purpose: Raynaud’s phenomenon (RP) seen in patients with an underlying autoimmune rheumatic disorder have both functional and structural dysfunction at the microvascular level and in…
Abstract Number: 0559 • ACR Convergence 2021
Targeting NNMT as a Novel Metabolic Approach to Treat Systemic Sclerosis
M.Asif Amin¹, Bo Shi², Pei-Suen Tsou¹, Swarna Bale¹, Phillip Campbell¹, Mikel Gurrea-Rubio¹, Mark Eckert³, Ernst Lengyel³, Johann Gudjonsson⁴ and Varga John¹, ¹University of Michigan, Ann Arbor, MI, ²Nothwestern university, Chicago, IL, ³University of chicago, Chicago, IL, ⁴Department of Dermatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Fibrosis, the hallmark of systemic sclerosis (SSc), is associated with metabolic and epigenetic alterations that are incompletely characterized. Our laboratory had previously implicated dysregulated…
Abstract Number: 1365 • ACR Convergence 2021
Release of High-Mobility Group Box-1 After an Raynaud’s Attack Potentially Leads to Fibroblast Activation and Interferon-γ Induced Protein-10 Production in Systemic Sclerosis
Isabella Atzeni¹, Yehya Al-Adwi², Berber Doornbos-van der Meer², Amel Eman Abdulle², Anniek Van Roon², Alja J. Stel², Harry Van Goor², Andries Smit², Johanna Westra² and Douwe J Mulder², ¹University of Groningen, University Medical Centre Groningen, Groningen, Groningen, Netherlands, ²University of Groningen, University Medical Centre Groningen, Groningen, Netherlands
Background/Purpose: Raynaud’s Phenomenon (RP) leading to repetitive ischaemia and reperfusion (IR) stress, is the first recognisable sign of systemic sclerosis (SSc). Although RP has been…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].